PMID- 28099196
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20231213
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Linking)
VI  - 40
IP  - 3
DP  - 2017 Apr
TI  - Use of Engineered Exosomes Expressing HLA and Costimulatory Molecules to Generate 
      Antigen-specific CD8+ T Cells for Adoptive Cell Therapy.
PG  - 83-93
LID - 10.1097/CJI.0000000000000151 [doi]
AB  - Dendritic cell-derived exosomes (DEX) comprise an efficient stimulator of T 
      cells. However, the production of sufficient DEX remains a barrier to their broad 
      applicability in immunotherapeutic approaches. In previous studies, genetically 
      engineered K562 have been used to generate artificial antigen presenting cells 
      (AAPC). Here, we isolated exosomes from K562 cells (referred to as CoEX-A2s) 
      engineered to express human leukocyte antigen (HLA)-A2 and costimulatory 
      molecules such as CD80, CD83, and 41BBL. CoEX-A2s were capable of stimulating 
      antigen-specific CD8 T cells both directly and indirectly via CoEX-A2 
      cross-dressed cells. Notably, CoEX-A2s also generated similar levels of HCMV 
      pp65-specific and MART1-specific CD8 T cells as DEX in vitro. The results suggest 
      that these novel exosomes may provide a crucial reagent for generating 
      antigen-specific CD8 T cells for adoptive cell therapies against viral infection 
      and tumors.
FAU - Kim, Sueon
AU  - Kim S
AD  - *Catholic Hematopoietic Stem Cell Bank double daggerCancer Research Institute daggerDepartments of 
      Microbiology, College of Medicine, The Catholic University of Korea, Seoul, 
      Korea.
FAU - Sohn, Hyun-Jung
AU  - Sohn HJ
FAU - Lee, Hyun-Joo
AU  - Lee HJ
FAU - Sohn, Dae-Hee
AU  - Sohn DH
FAU - Hyun, Seung-Joo
AU  - Hyun SJ
FAU - Cho, Hyun-Il
AU  - Cho HI
FAU - Kim, Tai-Gyu
AU  - Kim TG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (4-1BB Ligand)
RN  - 0 (Antigens, CD)
RN  - 0 (B7-1 Antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Immunoglobulins)
RN  - 0 (MART-1 Antigen)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (cytomegalovirus matrix protein 65kDa)
SB  - IM
MH  - 4-1BB Ligand/genetics/metabolism
MH  - Antigens, CD/genetics/metabolism
MH  - B7-1 Antigen/genetics/metabolism
MH  - CD8-Positive T-Lymphocytes/*immunology/transplantation
MH  - Cross-Priming
MH  - Dendritic Cells/pathology
MH  - Exosomes/genetics/*metabolism/pathology
MH  - Genetic Engineering
MH  - HLA-A2 Antigen/genetics/metabolism
MH  - Humans
MH  - Immunoglobulins/genetics/metabolism
MH  - Immunotherapy, Adoptive/*methods
MH  - K562 Cells
MH  - Lymphocyte Activation
MH  - MART-1 Antigen/immunology
MH  - Membrane Glycoproteins/genetics/metabolism
MH  - Neoplasms/immunology/*therapy
MH  - Phosphoproteins/immunology
MH  - Viral Matrix Proteins/immunology
MH  - Virus Diseases/immunology/*therapy
MH  - CD83 Antigen
EDAT- 2017/01/19 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/01/19 06:00
PHST- 2017/01/19 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
PHST- 2017/01/19 06:00 [entrez]
AID - 10.1097/CJI.0000000000000151 [doi]
PST - ppublish
SO  - J Immunother. 2017 Apr;40(3):83-93. doi: 10.1097/CJI.0000000000000151.